| News Releases (Archive) |
SWOG Renews Focus on Gynecologic Malignancies
[Apr. 30, 2008]
|
SWOG has reactivated its Gynecologic Cancer Committee with a $250,000 grant from the Marsha Rivkin Center for Ovarian Cancer Research. This one-time grant to the Hope Foundation, the philanthropic arm of SWOG, will defer the expense associated with the start-up of this committee, including costs associated with coordination of education and research initiatives. See the press release.
|
| |
New Finasteride Findings from PCPT
[Oct. 1, 2007]
|
|
A newly published PCPT follow-up study, along with two others published recently, strongly suggests that finasteride makes it easier for physicians to detect high-grade cancers early by improving screening tests and prostate biopsy itself. This casts further light on an initially puzzling finding of PCPT: Men who took finasteride but still developed prostate cancer by the end of that study had higher rates of detected high-grade tumors than did men in the placebo group. News Release.
|
| |
2007 Young Investigators Selected
[Sep. 1, 2007]
|
|
Four talented young investigators were chosen after a rigorous and competitive application process to participate in The “Young Investigators” Training Course this Fall. The course includes intensive study of statistical principles, data collection and analysis, critical decision-making, protocol development and Southwest Oncology Group procedures to learn how to design a clinical trial.
|
| |
S9921 Closed
[Jan. 22, 2007]
|
|
S9921, a Southwest Oncology Group study entitled "Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy, Phase III," has been closed because of safety concerns. For details, see the news release.
|
| |
Prostate Cancer RT Treatment Outcomes Analyzed
[Jan. 17, 2007]
|
|
Results of a SWOG study show that radiotherapy given to locally advanced prostate cancer patients after prostatectomy does not significantly reduce the risk of subsequent cancer spread to distant sites, but does significantly lower the risk of local cancer recurrence compared to men who do not receive radiation. News Release
|
| |
Young Investigators Complete Training
[Sep. 30, 2006]
|
|
Six talented cancer researchers, chosen through a competitive process, completed the Southwest Oncology Group Young Investigators Training Course in September. The course puts the physicians on a fast track to develop and conduct cancer clinical trials through the Southwest Oncology Group. Press Release contains details.
|
| |
Innovative Prognostic Indicator Breast Trial
[Sep. 1, 2006]
|
|
Newly-opened Southwest Oncology Group study S0500 will seek to find out whether circulating tumor cells can be used to predict which women with metastatic breast cancer are responding well to a particular treatment and which are not. Early identification of those not responding to treatment will allow for more timely consideration of other treatment options. News Release
|
| |
Young Investigators Complete Training
[Sep. 22, 2005]
|
Four talented cancer researchers, chosen through a competitive process, just completed the Southwest Oncology Group Young Investigators Training Course. The course puts the physicians on a fast track to develop and conduct cancer clinical trials through the Southwest Oncology Group. Press Release contains details. Photo
|
| |
PSA's Validity as a Screening Test Evaluated
[Jul. 11, 2005]
|
A new data analysis from the Prostate Cancer Prevention Trial shows that Prostate-Specific Antigen is frequently inaccurate in testing for prostate cancer risk. Read more about it in the press release and the abstract. The data analysis was led by PCPT Study Coordinator Ian M. Thompson, Jr., M.D.
|
| |
S0023 Closed
[Apr. 18, 2005]
|
|
The National Cancer Institute issued a press release on April 18, 2005 announcing the closure of Southwest Oncology Group study S0023. This is a randomized trial for patients with locally advanced non-small cell lung cancer comparing gefitinib (Iressa™) versus a placebo following chemotherapy and radiation. A review of interim data has indicated that gefitinib would not improve survival. Detailed results from the study will be presented at the American Society of Clinical Oncology annual meeting May 13-17.
|
| |
| News Releases |
| |
| SWOG in the News (Archive) |
NCI-Sponsored Cancer Trials Offer Decent Clinical Return on Investment
[Mar. 24, 2008]
|
|
MedPage Today reported on a study by Dr. Benjamin Djulbegovic, et.al., which showed that clinical trials conducted by the National Cancer Institute's Cooperative Groups, including SWOG, were beneficial in driving therapeutic advances in clinical medicine.
|
| |
Prostate Cancer RT Treatment Outcomes Analyzed
[Sep. 1, 2007]
|
|
Results of a SWOG study show that radiotherapy given to locally advanced prostate cancer patients after prostatectomy does not significantly reduce the risk of subsequent cancer spread to distant sites, but does significantly lower the risk of local cancer recurrence compared to men who do not receive radiation.
|
| |
SWOG Chair receives Sarcoma Foundation Award
[May. 22, 2006]
|
 On May 22, SWOG Chairman Laurence H. Baker, D.O., was presented the Sarcoma Foundation of America’s Nobility in Science Award for his 34-year commitment to the advancement of scientific knowledge about sarcoma. News Release
|
| |
New Standard Treatment for Advanced Ovarian Cancer
[Jan. 6, 2006]
|
|
NCI released a clinical announcement on January 5, 2006, concerning recommended treatment for advanced ovarian cancer. Southwest Oncology Group trials helped solidify evidence for this recommendation.
Read the SWOG news release here concerning the Group's participation in the science that led to this announcement.
Based on the results of eight phase III clinical trials, including SWOG-8501 and GOG-114 (SWOG-9227), NCI is encouraging doctors to follow surgery with a combination of two drug-delivery methods: intravenous and intraperitoneal. The combined approach, though more toxic, extends overall survival for women with advanced ovarian cancer by about a year compared to intravenous delivery alone.
|
| |
| SWOG in the News |
| |
